.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,469,012

« Back to Dashboard
Patent 6,469,012 protects VIAGRA and is included in one NDA. There have been two Paragraph IV challenges on Viagra. There are eleven tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for VIAGRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in twenty-six countries.

Summary for Patent: 6,469,012

Title: Pyrazolopyrimidinones for the treatment of impotence
Abstract:The use of a compound of formula (I) ##STR1## wherein R.sup.1 is H; C.sub.1 -C.sub.3 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.5 cycloalkyl; R.sup.2 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.3 perfluoroalkyl; or C.sub.3 -C.sub.6 cycloalkyl; R.sup.3 is optionally substituted C.sub.1 -C.sub.6 alkyl; C.sub.1 -C.sub.6 perfluoroalkyl; C.sub.3 -C.sub.5 cycloalkyl; C.sub.3 -C.sub.6 alkenyl; or C.sub.3 -C.sub.6 alkynyl; R.sup.4 is optionally substituted C.sub.1 -C.sub.4 alkyl, C.sub.2 -C.sub.4 alkenyl, C.sub.2 -C.sub.4 alkanoyl, (hydroxy)C.sub.2 -C.sub.4 alkyl or (C.sub.2 -C.sub.3 alkoxy)C.sub.1 -C.sub.2 alkyl; CONR.sup.5 R.sup.6 ; CO.sub.2 R.sup.7 ; halo; NR.sup.5 R.sup.6 ; NHSO.sub.2 NR.sup.5 R.sup.6 ; NHSO.sub.2 R.sup.8 ; SO.sub.2 NR.sup.9 R.sup.10 ; or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl; R.sup.5 and R.sup.6 are each independently H or C.sub.1 -C.sub.4 alkyl, or together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino, 4-N(R.sup.11)-piperazinyl or imidazolyl group; R.sup.7 is H or C.sub.1 -C.sub.4 alkyl; R.sup.8 is optionally substituted C.sub.1 -C.sub.3 alkyl; R.sup.9 and R.sup.10 together with the nitrogen atom to which they are attached form an optionally substituted pyrrolidinyl, piperidino, morpholino or 4-N(R.sup.12)-piperazinyl group; R.sup.11 is H; optionally substituted C.sub.1 -C.sub.3 alkyl; (hydroxy)C.sub.2 -C.sub.3 alkyl; or C.sub.1 -C.sub.4 alkanoyl; R.sup.12 is H; optionally substituted C.sub.1 -C.sub.6 alkyl; CONR.sup.13 R.sup.14 ; CSNR.sup.13 R.sup.14 ; or C(NH)NR.sup.13 R.sup.14 ; and R?13? and R.sup.14 are each independently H; C.sub.1 -C.sub.4 alkyl; or substituted C.sub.2 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said male animal with said pharmaceutical composition or with said either entity.
Inventor(s): Ellis; Peter (Sandwich, GB), Terrett; Nicholas Kenneth (Sandwich, GB)
Assignee: Pfizer Inc (New York, NY)
Application Number:08/549,792
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-001Mar 27, 1998RXNo6,469,012*PED► subscribeY
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-002Mar 27, 1998RXNo6,469,012*PED► subscribeY
Pfizer Ireland
VIAGRA
sildenafil citrate
TABLET;ORAL020895-003Mar 27, 1998RXYes6,469,012*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,469,012

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9311920Jun 09, 1993
PCT Information
PCT FiledMay 13, 1994PCT Application Number:PCT/EP94/01580
PCT Publication Date:December 22, 1994PCT Publication Number: WO94/28902

International Patent Family for Patent: 6,469,012

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria163852► subscribe
Australia676571► subscribe
Australia6797394► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc